Biogen
- Market cap
- 32.82B
- P/E (TTM)i
- 39.46
- P/Bi
- 1.74
- EPSi
- 8.79
- Div yieldi
- 0.00%
- 52W posi
- 91%
Anonymous reader poll. Unscientific, not investment advice.
Biogen last traded at 222.15, down 0.33% on the session. Its market capitalisation is about 32.82B, the #623 most valuable US-listed company we track. Trading at a P/E of 40.12, the stock is 110% above its own five-year norm of 19.14. Wall Street's 26-analyst consensus lands on Buy, with a price target averaging 239.95 (+8% from here). Against a 52-week band of 138.00-230.49, the shares are currently 91% of the way up.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 20% of the universe, above its 200-day average.
- Signal has read BUY for 4 months.
- Recent price momentum is +27.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 3.9% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation D+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 39.7x | Better than 17% |
| Forward P/E | 25.5x | Better than 28% |
| Price / Sales | 3.3x | Better than 43% |
| P/E vs own 5-yr range | 100th pctl | Better than 1% |
Growth C-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -0.9% | Better than 18% |
| Net income CAGR (3Y) | -24.9% | Better than 12% |
| Free cash flow CAGR (3Y) | 19.9% | Better than 65% |
Profitability B
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 75.7% | Better than 88% |
| Operating margin | 25.0% | Better than 76% |
| Net margin | 13.1% | Better than 57% |
| Return on equity | 7.4% | Better than 28% |
| Return on invested capital | 6.1% | Better than 34% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 8.7% | Better than 74% |
| 6-month return | 27.3% | Better than 78% |
| 12-month return (ex latest month) | 43.3% | Better than 77% |
| Distance below 52-week high | 3.0% | Better than 94% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.7x | Better than 78% |
| Debt to assets | 22.3% | Better than 61% |
| Interest coverage | 6.8x | Better than 52% |
| Free cash flow / net income | 152.3% | Better than 74% |
Analyst View C-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 65.4% | Better than 40% |
| Upside to average target | 7.3% | Better than 12% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 222.89
- Open
- 222.93
- Day range
- 221.40 - 228.00
- Avg price
- 224.19
- Volume
- 1.30M
- Turnover
- 291.04M
- Turnover ratei
- 0.88%
- Volume ratioi
- 1.07
- Amplitudei
- 2.96%
- 52-week rangei
- 138.00 - 230.49
Valuation
- P/Ei
- 25.27
- P/E (TTM)i
- 39.46
- P/Bi
- 1.74
- EPSi
- 8.79
- Book value / shi
- 127.56
- Net profit
- 1.30B
- Net assets
- 18.85B
Share structure
- Market cap
- 32.82B
- Float capi
- 32.70B
- Shares out
- 147.75M
- Float sharesi
- 147.22M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
3.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-24.12M net over the window
Short interest
- Shares short
- 5.82M
- % of floati
- 3.94%
- Days to coveri
- 7.59
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Biogen (BIIB)?
Biogen last traded at 222.15. The quote on this page refreshes every few seconds while US markets are open.
What is Biogen's market cap?
About 32.82B.
What is the P/E ratio of Biogen?
The trailing twelve-month P/E is 39.46, above its own 5-year average of 19.14 — toward the top of its historical range (99.60% percentile). See the Valuation tab for the full history.
Does Biogen pay a dividend?
Biogen does not currently pay a regular dividend.
Is Biogen a buy according to analysts?
The consensus of 26 analysts is a Buy rating, with an average 12-month price target of 239.95, which implies 8.0% upside from the current price. This is not investment advice.
What is Biogen's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Biogen a B (Buy). Twelve-month momentum in the top 20% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 04:46:37 · For reference only, not investment advice and not tailored to your situation.